Moderna MRNA
NASDAQ MRNA
$254.19 +12.73 (+5.27%)
At close: Nov 6, 2026 · 4:00 PM EST

Moderna (MRNA) Preferred Stock Liabilities (2017)

Updated

Moderna's Preferred Stock Liabilities came in at $1.18 billion for Q4 2017.

Analysis

Moderna (MRNA) Preferred Stock Liabilities (2017) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $1.18 billion in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,224.11 Bn 1,197.72 Bn 20.46 Bn -
2 Johnson & Johnson 665.34 Bn 585.20 Bn 17.30 Bn -
3 AbbVie 515.72 Bn 483.73 Bn 13.12 Bn -
4 Merck 362.64 Bn 325.58 Bn 13.19 Bn -
5 Novartis Ag 315.51 Bn 288.75 Bn - -
6 Astrazeneca 289.26 Bn 263.15 Bn 13.26 Bn -
7 Amgen 249.20 Bn 200.85 Bn 7.58 Bn -
8 Gilead Sciences 207.48 Bn 182.59 Bn 6.73 Bn -
9 Pfizer 167.49 Bn 114.85 Bn 12.56 Bn -
10 Moderna 100.92 Bn 80.27 Bn 52.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 1.18 Bn
API Access

Moderna Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MRNA&period=max&api_key=YOUR_API_KEY